Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature

Pediatric Pulmonology

Volumn 44, Issue 9, 2009, Pages 922-934

  Bitzan, Martin ^a   Anselmo, Mark ^a   Carpineta, Lucy ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

B cell depletion; Cryptogenic organizing pneumonia; Focal segmental glomerulosclerosis; Interstitial lung disease; Nephrotic syndrome; Pneumonitis

Indexed keywords

AMOXICILLIN; CEFTRIAXONE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOGLOBULIN E; LEVAMISOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

ACNE; ADOLESCENT; ADRENAL INSUFFICIENCY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; B LYMPHOCYTE; CASE REPORT; CLINICAL FEATURE; CUSHINGOID SYNDROME; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SUBSTITUTION; DYSPNEA; FATIGUE; FEVER; FOCAL GLOMERULOSCLEROSIS; GINGIVA HYPERPLASIA; GRAFT VERSUS HOST REACTION; HIRSUTISM; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOXEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN DEFICIENCY; INFLAMMATORY CELL; KIDNEY BIOPSY; LUNG INFILTRATE; LUNG INJUIRY; LUNG INJURY; LUNG LAVAGE; LYMPHOCYTE DEPLETION; MALE; MICROBIOLOGY; NEPHROTIC SYNDROME; OBESITY; OUTCOME ASSESSMENT; PEDIATRICS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CRYPTOGENIC ORGANIZING PNEUMONIA; HUMANS; LUNG INJURY; LYMPHOCYTE DEPLETION; MALE;

EID: 69749083478     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20864     Document Type: Article

References (78)

1. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-454. (Pubitemid 24272191)
2. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-1685.
3. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9.
4. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195. (Pubitemid 27392702)
5. Anonymus, Rituxan (Rituximab). Volume 2008: Genentech USA, Inc. Biogen Idec, Inc; 2007.
6. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006; 20:915-928. (Pubitemid 44382384)
7. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003;14:1851-1857. (Pubitemid 36750480)
8. Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008;28:205-215.
9. Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 2007;72:676-682. (Pubitemid 47373785)
10. Goldblatt F, Isenberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Handb Exp Pharmacol 2008;181:163-181.
11. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005;20:1660-1663. (Pubitemid 41554486)
12. van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 2008;50:886-888. (Pubitemid 351354810)
13. Berentsen S. Rituximab for the treatment of autoimmune cytopenias. Haematologica 2007;92:1589-1596.
14. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2007;50:822-825. (Pubitemid 351354792)
15. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, Deschenes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:623-627. (Pubitemid 43776914)
16. Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B-Cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008;95:401-406. (Pubitemid 352025791)
17. Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 2008;23:413-419.
18. Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004;19:794-797. (Pubitemid 38931165)
19. Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008;23:481-485.
20. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007;356: 2751-2752. (Pubitemid 47001064)
21. Bitzan M, Ouahed JD, Krishnamoorthy P, Bernard C. Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution. Pediatr Nephrol 2008;23:1355-1361.
22. Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007;34:430-433.
23. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 1999;94:2217-2224. (Pubitemid 29467667)
24. Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2:378-384. (Pubitemid 34048661)
25. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-811.
26. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999;17:791-795. (Pubitemid 29109307)
27. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14. (Pubitemid 36025880)
28. Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin C Jr, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma 2003; 4:36-42. (Pubitemid 36826875)
29. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007;109:2182-2189. (Pubitemid 46805005)
30. Grim SA, Pham T, Thielke J, Sankary H, Oberholzer J, Benedetti E, Clark NM. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007;21:628-632. (Pubitemid 47399427)
31. Heresi GA, Farver CF, Stoller JK. Interstitial Pneumonitis and Alveolar Hemorrhage Complicating Use of Rituximab. Case Report and Reviewof the Literature. Respiration 2008;76:449-453.
32. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-919.
33. Schlesinger C, Koss MN. The organizing pneumonias: an update and review. Curr Opin Pulm Med 2005;11:422-430.
34. Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004;45: 2321-2325. (Pubitemid 39504329)
35. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004;79: 949, 953.
36. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006;354:1961-1963. (Pubitemid 43872718)
37. Abitbol C, Zilleruelo G, Freundlich M, Strauss J. Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children. J Pediatr 1990; 116:243-247. (Pubitemid 20056779)
38. Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, Katoh N, Kishimoto S, Shimazaki C. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172-173.
39. Swords R, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004;77:103-104. (Pubitemid 39108808)
40. Emmanouilides C, Territo M, Menco H, Patel R, Rosen P. Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. Hematol Oncol 2003;21:99-108. (Pubitemid 37305329)
41. Macartney C, Burke E, Elborn S, Magee N, Noone P, Gleadhill I, Allen D, Kettle P, Drake M. Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma 2005;46: 1523-1526. (Pubitemid 41479597)
42. Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-Pediatric cell lymphoma: case report and review of the literature. Leuk Lymphoma 2006;47:1683-1685. (Pubitemid 44364040)
43. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005;81:169-170. (Pubitemid 40270992)
44. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001;42:1329-1337. (Pubitemid 34082922)
45. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003;348:2690-2691. discussion 2690-2691.
46. Herishanu Y, Polliack A, Leider-Trejo L, Grieff Y, Metser U, Naparstek E. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 2006;6:407-409.
47. Lee Y, Kyung SY, Choi SJ, Bang SM, Jeong SH, Shin DB, Lee JH. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006;21:183-186. (Pubitemid 44823261)
48. Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 2006;24:234-237. (Pubitemid 46032898)
49. Zerga M, Cerchetti L, Cicco J, et al. Desquamative alveolitis: an unusual complication of treatment with mabthera. Blood 1999; 94:271S.
50. Jullien V, Perrin C, Peyrade F, Lemoigne F, Chichmanian RM, Blaive B. Alveolar hypoxemic interstitial pneumonia related to rituximab therapy. Rev Mal Respir 2004;21:407-410.
51. Ghesquieres H. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 2005;16:1399. (Pubitemid 41158487)
52. Motl SE, Baskin RC. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy 2005;25:1151-1155. (Pubitemid 41099452)
53. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-1857. (Pubitemid 29269257)
54. Gray ND, Brath LK. Fatal diffuse alveolar damage related to rituximab. Chest 2007;132:724S.
55. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, Grewal IS. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006;148:1116-1123. (Pubitemid 44223017)
56. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007;44:1331-1341. (Pubitemid 44415959)
57. Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008;111: 2211-2219.
58. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999;10:529-537. (Pubitemid 29117634)
59. Kemper MJ, Zepf K, Klaassen I, Link A, Muller-Wiefel DE. Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse. Am J Nephrol 2005;25:132-137. (Pubitemid 40864182)
60. Mansour H, Cheval L, Elalouf JM, Aude JC, Alyanakian MA, Mougenot B, Doucet A, Deschenes G. T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome. Kidney Int 2005;67:2168-2177. (Pubitemid 41623378)
61. Dotsch J, Muller-Wiefel DE, Kemper MJ. Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible? Pediatr Nephrol 2008; 23:3-7.
62. Kemper MJ, Moeller C, Rink N, van Husen M, Mueller-Wiefel DE. Treatment of refractory steroid sensitive nephrotic syndrome (SSNS) with rituximab (RTX). Pediatr Nephrol 2007;22:1445.
63. Bitzan M, Mamber S, Ouahed JD. Rituximab treatment of children with steroid-dependent and frequently relapsing nephrotic syndrome. Iranian J Kidney Dis 2007;1:32.
64. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-2982.
65. Sampath S, Schultheiss TE, Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 2005;63:876-884. (Pubitemid 41400079)
66. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 2006;4:1059-1070.
67. Helman DL Jr, Byrd JC, Ales NC, Shorr AF. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest 2002;122:785-790.
68. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006;17:372-379. (Pubitemid 43329572)
69. Hasegawa Y, Ninomiya H, Kamoshita M, Ohtani K, Kobayashi T, Kojima H, Nagasawa T, Abe T. Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma. Intern Med 1997;36:360-364. (Pubitemid 27321583)
70. van der Kolk LE, de Haas M, Grillo-Lopez AJ, Baars JW, van Oers MH. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 2002;16:693-699. (Pubitemid 34449752)
71. Respiratory ATSE. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165: 277-304.
72. du Bois R, King TE Jr. Challenges in pulmonary fibrosis × 5: the NSIP/UIP debate. Thorax 2007;62:1008-1012.
73. Mueller-Mang C, Grosse C, Schmid K, Stiebellehner L, Bankier AA. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics 2007;27:595-615.
74. Nathan SD. Therapeutic intervention: assessing the role of the international consensus guidelines. Chest 2005;128:533S-539S.
75. Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004;125: 70S-78S.
76. Abe S, Nakamura H, Inoue S, Takeda H, Saito H, Kato S, Mukaida N, Matsushima K, Tomoike H. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;22:51-60. (Pubitemid 30342959)
77. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;290:L75-85.
78. El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 2007;150:376-382. (Pubitemid 46437325)